Stemline Therapeutics, Inc. Announces Closing of $60 Million Public Offering of Common Stock

Published: May 22, 2013

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

NEW YORK, May 22, 2013 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML), a clinical-stage biopharmaceutical company developing oncology therapeutics that target both cancer stem cells (CSCs) and tumor bulk, today announced the closing of its previously announced underwritten public offering of 4,137,931 shares of its common stock at a public offering price of $14.50 per share. The gross proceeds to Stemline from the public offering are $60 million, before underwriting discounts and commissions and other offering expenses payable by Stemline.

Help employers find you! Check out all the jobs and post your resume.

Back to news